医学
嵌合抗原受体
细胞疗法
T细胞受体
受体
抗原
免疫疗法
免疫学
肿瘤科
癌症研究
T细胞
内科学
细胞
免疫系统
遗传学
生物
作者
Shalini Srivastava,Sanjay Singh,Ajay Singh
标识
DOI:10.1080/14737140.2024.2372330
摘要
The inception of recombinant DNA technology and live cell genomic alteration have paved the path for the excellence of cell and gene therapies and often provided the first curative treatment for many indications. The approval of the first Chimeric Antigen Receptor (CAR) T-cell therapy was one of the breakthrough innovations that became the headline in 2017. Currently, the therapy is primarily restricted to a few nations, and the market is growing at a CAGR (current annual growth rate) of 11.6% (2022-2032), as opposed to the established bio-therapeutic market at a CAGR of 15.9% (2023-2030). The limited technology democratization is attributed to its autologous nature, lack of awareness, therapy inclusion criteria, high infrastructure cost, trained personnel, complex manufacturing processes, regulatory challenges, recurrence of the disease, and long-term follow-ups.
科研通智能强力驱动
Strongly Powered by AbleSci AI